University Hospital and New Jersey Medical School (NJMS) are, through their joint FDA-approved convalescent plasma program, collecting plasma donations from patients who have recovered from COVID-19 and infusing it into patients still struggling to fight off the virus. Marc Klapholz, chair of NJMS” Department of Medicine and the hospital’s chief of medical service, explains that the presumed antibodies in the plasma may improve seriously ill patients’ chances for survival. To read the full article.
Recent Posts
- NJACTS Community Engagement Core Available Services
- Join NJ ACTS for a Seminar on Clinical Research Record Retention on 3/2 at 12
- CTSA Translational Impact Summit on March 2&3 (Virtual) – Register Now!
- Join NJ ACTS for Boosted: The Impact of Science, Society, and Policy on Public Health on 2/27 at 12
- NJACTS Community Engagement Core COVID-19 Resources
Categories
- Community (2,440)
- Covid (997)
- CTO Events (6)
- News (3,092)
- Pilots (21)